Randomized, Double-blind Trial Evaluating the Safety and Efficacy of a 21-day Course of Albendazole 400mg/Day in Subjects With High Loa Loa Microfilaremia

Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.

Start Date15 Jan 2025

Sponsor / Collaborator

Institut de Recherche pour le Développement

PACTR202411565966953

/ SuspendedNot Applicable

Open label, balanced, randomized, two-treatment, four-period, two-sequence, single oral dose, full replicate crossover, bioequivalence study of Albendazole Tablets IP 400 mg of Fidson with Zentel® Tablets 400 mg of GSK in healthy, adult male and female participants under fed conditions.

Start Date01 Jan 2025

Sponsor / Collaborator

Fidson Healthcare Plc

CTRI/2024/07/070861

/ Not yet recruitingPhase 2/3IIT

A comparative clinical trial to study the effect of Triphaladi ghrita and albendazole in the management of Krimi roga in children. - NIL

Start Date15 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Albendazole

100 Translational Medicine associated with Albendazole

100 Patents (Medical) associated with Albendazole

10,313

Literatures (Medical) associated with Albendazole

01 Apr 2025·International Journal for Parasitology: Parasites and Wildlife

A combined treatment regimen for Trichuris rhinopiptheroxella infection in Rhinopithecus roxellana in southern China

Article

Author: Xiao, Lihua ; Yuan, Dongjuan ; Dong, Guixin ; Zhang, Peng ; Feng, Yaoyu ; Ren, Zhengjiu ; Zhang, Tianyou ; Lu, Jinzhi

The Sichuan snub-nosed monkey (Rhinopithecus roxellana) is an endangered species in China and is susceptible to infection with Trichuris species. However, the worms are difficult to remove completely. A practical treatment regimen for trichuriasis was conducted over a seven-month period on 15 R. roxellana in a wildlife zoo in southern China. Initially, a combination of fecal examination, morphological observation, molecular identification of ITS1 and mitogenome, and infective pattern analysis revealed that R. roxellana was susceptible to Trichuris rhinopiptheroxella. Three rounds of treatment were administrated, with a dosage of 10 mg/kg albendazole or ivermectin in each. The initial administration of albendazole to 15 monkeys resulted in a reduction of fecal eggs per gram (EPG) by 7.8%-73.2%. The subsequent administration of albendazole to 9 monkeys demonstrated a reduction in fecal EPG by 52.6%-52.8%. The third administration of ivermectin to 5 monkeys resulted in a reduction of fecal EPG by 55.6%-96.6%. However, the EPG level increased in some monkeys after one month of these three anthelmintic administrations. Subsequently, improved strategies were implemented, including an increased dosage of albendazole, flame sterilization, the replacement of the sandy floor with concrete, and the hanging of food. Results showed that a reduction in the fecal EPG of 8 monkeys in the exhibition region, with a decrease from 5135 to 63. Additionally, 6 monkeys exhibited a negative EPG after one month. In the breeding region, the fecal EPG of 7 monkeys decreased from 7389 to 869. Additionally, 2 monkeys demonstrated a negative EPG after one month. This study provides evidence for the control of Trichuris infection in R. roxellana and offers a guideline for the treatment of trichuriasis in animals.

01 Apr 2025·International Journal for Parasitology: Drugs and Drug Resistance

Efficacy of fenbendazole against gastrointestinal nematodes in naturally infected goats in Maputo Province, Mozambique using in vivo, in vitro and molecular assessment

Article

Author: Krücken, Jürgen ; Afonso, Sonia M S ; Borchert, Marc ; Atanásio, Alsácia ; von Samson-Himmelstjerna, Georg ; Guinda, Edna F X ; Morgan, Eric R ; Capece, Bettencourt P S ; Ramünke, Sabrina ; Fiedler, Stefan

Anthelmintic resistance occurs worldwide in strongyles of ruminants but data from low-income countries are sparse and rarely apply most up to date methods, while effects of management practices in these countries are poorly documented. In Mozambique, benzimidazole resistance has been previously reported; the present study followed this up in detail, applying in vivo faecal egg count (FEC) reduction test (FECRT), in vitro egg hatch test (EHT) and molecular deep amplicon sequencing approaches targeting the internal transcribed spacer 2 (ITS-2, nemabiome) and the isotype 1 β-tubulin gene to determine the resistance status on farms and the strongyle species involved. Adult Landim goats (433) from six semi-intensive and ten extensive farms (22-30 animals/farm) from Maputo Province were visited April 2021 to February 2022. Fenbendazole (5 mg/kg bw, Panacur®) was administered orally and FEC determined using Mini-FLOTAC. The eggCounts package was used to calculate FECRs with 90% confidence intervals from paired day 0 and 14 data. In vivo and in vitro tests detected AR on 5/16 (31%) farms. This included 1/10 extensive and 4/6 semi-intensive farms. The odds of finding resistant strongyles on a semi-intensive commercial farm was 40-fold higher than on an extensive farm (p = 0.016, logistic regression). A strong, negative correlation was observed between FECRT and EHT EC₅₀ values (Pearson's R = -0.83, P = 0.001; Cohen's κ coefficient 1.0). Nemabiome data showed that Haemonchus contortus, Trichostrongylus colubriformis and unclassified Oesophagostomum closely related to Oesophagostomum columbianum were most abundant before treatment and in particular H. contortus frequencies increased after treatment. Benzimidazole resistance associated polymorphisms were detected in H. contortus and T. colubriformis. Moreover, there were hints that resistance alleles were present in Trichostrongylus axei and Teladorsagia circumcincta. Farmers should regularly test the efficacy of anthelmintics used and consider more sustainable worm control approaches to reduce selection for resistance.

01 Apr 2025·Journal of Colloid and Interface Science

Understanding drug solubilization in intestinal mixed micelles through molecular dynamics simulations

Article

Author: Ivanova, Anela ; Genchev, Nikola ; Bevernage, Jan ; Vinarova, Liliya ; Vinarov, Zahari ; Tcholakova, Slavka ; Mustan, Fatmegyul ; Tistaert, Christophe

HYPOTHESISSolubilization is a fundamental process that underpins various technologies in the pharmaceutical and chemical industry. However, knowledge of the location, orientation and interactions of solubilized molecules in the micelles is still limited. We expect all-atom molecular dynamics simulations to improve the molecular-level understanding of solubilization and to enable its in silico prediction.METHODSThe solubilization of six drugs in intestinal mixed micelles composed of taurocholate and dioleoyl phosphatidylcholine was simulated by molecular dynamics in explicit water and measured experimentally by liquid chromatography. The location and orientation of the solubilized drugs were visualized by cumulative radial distribution functions and interactions were characterized by radial distribution function ratios and hydrogen bonding.FINDINGSA new simulation-derived parameter was defined, which accounts for drug-micelle and drug-water interactions and correlates (R² = 0.83) with the experimentally measured solubilization. Lipophilicity was found to govern the location of all drugs in the micelle (hydrophobic core, palisade layer or on the surface), while hydrogen bonding was crucial for orientation and solubilization of two of the molecules. The study demonstrates that explicit, hydrogen bond-forming water molecules are vital for accurate prediction of solubilization and provides a comprehensive framework for quantitative studies of drug location and orientation within the micelles.

News (Medical) associated with Albendazole

12 Nov 2024

·www.globenewswire.com

Timor-Leste eliminates lymphatic filariasis as a public health problem

DECATUR, Ga., Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Mectizan Donation Program applauds Timor-Leste for eliminating lymphatic filariasis (LF) as a public health problem, a remarkable achievement that was recently validated by the World Health Organization (WHO). Timor-Leste is the fifth country in Southeast Asia to achieve this milestone and the first country in the region to do so by co-administering Mectizan, albendazole and diethylcarbamazine (DEC). Since 2017, Merck (known as MSD outside of the U.S. and Canada), GSK and Eisai have been partnering to donate Mectizan, albendazole, and DEC, respectively, to accelerate the elimination of LF in eligible countries where river blindness is not endemic based on a recommendation of triple drug therapy from WHO. LF, commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted by mosquitoes. Long-term, chronic infection can cause damage to the lymphatic system, as well as severe and irreversible swelling to the limbs, breasts and/or genitals. These symptoms can cause extreme discomfort, disability and social stigmatization. “We are delighted to learn of Timor-Leste’s success in eliminating LF as a public health problem,” said Allison Goldberg, president, Merck Foundation. “This achievement is a testament to the strength and determination of the Timor-Leste people and the power of public-private partnerships, including the Mectizan Donation Program.”Thomas Breuer, Chief Global Health Officer at GSK, stated, “We congratulate Timor-Leste for this remarkable achievement. The elimination of lymphatic filariasis as a public health problem in Timor-Leste is demonstrative of the power of effective partnerships and the unwavering commitment of the global NTD community.” Mectizan Donation Program director Dr. Yao Sodahlon, an expert in tropical diseases who played a vital role in the elimination of LF in Togo, stated, “We celebrate the government of Timor-Leste, the endemic communities who helped distribute the medicines with high coverage demonstrating effectiveness of triple drug therapy, and the partners who made elimination of LF in Timor-Leste possible. This success demonstrates that elimination of LF can be achieved through the donations of these essential medicines, the commitment of the government and people of the endemic countries, and the global partnership working to end LF.” About the Mectizan Donation Program The Mectizan Donation Program (MDP) was established in 1987 to provide medical, technical, and administrative oversight of the donation of Mectizan by Merck for the treatment of onchocerciasis, also known as river blindness. In 1998, MDP expanded its mandate to include oversight of the donation of albendazole by GSK for the elimination of lymphatic filariasis in onchocerciasis co-endemic areas. Contacts MDP:Joni Lawrence Deputy Director Mectizan Donation Program jlawrence@taskforce.org Yao SodahlonDirectorMectizan Donation Programysodahlon@taskforce.org

10 Nov 2023

·synapse.patsnap.com

Latest Research Progress on TLR Adjuvants

The TLR agonists used in vaccine formulations come in various forms, ranging from lipopeptides to single-stranded DNA and RNA. Below, we will introduce the main categories of TLR adjuvants. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target. TLR2TLR2 is expressed on the surface of various cells, including monocytes, macrophages, endothelial cells, epithelial cells, natural killer cells, dendritic cells, myeloid-derived suppressor cells, platelets, and mast cells. The PAMP library recognized by TLR2 is the most extensive, as it can form heterodimers with TLR1 and TLR6 (and TLR10 in humans). The range of TLR2 adjuvants is extensive, including synthetic lipopeptides (PAM3CSK4 and PAM2CSK4), arabino-mannose lipids, phospholipidic acid, GPI membrane anchors, yeast polysaccharides, and peptidoglycans. Recent trends in TLR2 research include the discovery of small synthetic TLR2 agonists, improvements in the characteristics of traditional TLR2 agonists, and the bio-conjugation of TLR2 with vaccine antigens. For example, XS15 (PAM3CS-GDPKHPKSF) is a new TLR-1/2 agonist based on PAM3CS, where the four lysines (K4) of PAM3CSK4 are replaced with a nonapeptide (GDPKHPKSF) to alter the solubility of the conjugate, promoting uptake and facilitating purification. Constraints of using TLR2 agonists as adjuvants include the size, complexity, and hydrophobicity of most ligands. TLR3TLR3 is an intracellular recognition system that reacts to viral nucleic acids (dsRNA, ssRNA, and ssDNA) and endogenous double-stranded RNA. Many TLR3 agonists have been developed, such as RGC100 and ARNAX, a synthetic DNA-RNA hybrid compound. However, in the past two years, researchers have returned to using traditional dsRNA analog ligands, such as poly IC, focusing on improving their delivery modes and new disease applications. TLR4TLR4 is the most studied member of the TLR family, recognizing lipopolysaccharides (LPS). TLR4 is located on the cell membrane, mainly expressed on myeloid cells, but not on plasmacytoid dendritic cells (pDCs) and immature B cells. TLR4 recognizes LPS through its co-receptors myeloid differentiation factor-2 (MD-2) and CD14. Recent works on TLR4 agonists concentrate on the development and evaluation of modified products, such as monophosphoryl lipid A (MPLA) and Glucopyranosyl lipid A (GLA), which are structurally related to LPS, but have no high pyrogenicity while maintaining strong immunoenhancing characteristics, thus increasing their clinical feasibility. TLR5TLR5 recognizes flagellin protein and is expressed on epithelial cells and immune cells (such as macrophages and immature DC), generating immune responses through the MyD88-dependent signaling pathway. Recent work on TLR5 agonists has mainly focused on enhancing tolerance. Unfortunately, flagellin can induce unnecessary hyperreactivity, as a protein, it can induce antibodies against itself, interfering with its function as an adjuvant. This issue has been solved by research through removing the B cell epitope region from flagellin, the deimmunized flagellin retains its TLR5 adjuvant activity. TLR7/8TLR7 and TLR8 are located on the endosomal membrane of immune cells. TLR7 is primarily expressed in pDC and B cells, while TLR8 is expressed in myeloid dendritic cells and monocytes, with lower expression in pDC. TLR7/8 recognizes single-strand ribonucleic acid (ssRNA), and signals through the MyD88-dependent pathway. Among natural ligands, oligonucleotides (ORNs) enriched with adenine and uridine can activate TLR8 without any effect on TLR7. However, ORNs enriched in guanine activate TLR7 and TLR8-dependent signal transduction. TLR7 exists as a monomer and dimerizes in the presence of ligand, while TLR8 exists as weakly dimerized in its natural state and undergoes conformational change when ligand binds. To date, more than15 novel heterocyclic molecules, such as imidazoquinoline, oxazine, pyrimidine, pyridopyrimidine, pyrrolopyrimidine and benzimidazole, have been identified as TLR7/8 agonists. A common drawback of TLR7/8 agonists is their reactogenicity, and in recent years, numerous studies have attempted to overcome these adverse effects. Encapsulating TLR7/8 agonists in nanoparticles based on cationic DOEPC liposome formulations, or covalently linking these small molecules to hyperbranched polymers, can avoid their harmful systemic reactions while preserving their impact on humoral immunity. TLR9TLR9 is located within the endosomal membrane in cells, recognizing the single-stranded unmethylated CpG oligonucleotides of bacteria and virus DNA. TLR9 is expressed on immune cells such as dendritic cells, macrophages, natural killer cells, and other APCs. Synthetic CpG sequences can be used as TLR9 agonists to enhance the immune response of vaccines, and each unique sequence variant combination has been proven to have different structural and biological characteristics. The latest developments in TLR9 agonists in the past two years have mainly focused on the efficient delivery and uptake of CpG to cells. For example, one study introduced a new method of conjugating CpG-ODN to novel cationic liposomes, this compound can induce a strong immune response at low antigen and adjuvant doses. Combined TLR AdjuvantsCombining different TLR agonists in a single vaccine can generate a synergistic effect, driving potent vaccine immune responses. For example, liposomal adjuvants containing 1V270 (TLR7 agonist) and 2B182C (TLR4 agonist) induced balanced anti-HA and anti-NA IgG1 and IgG2a responses against influenza, without the overreactivity commonly associated with Th1 proinflammatory responses. Similarly, one study assessed the co-encapsulation of ovalbumin (OVA) with ten unique combinations of two to three TLR ligands, including Pam3CSK4 (TLR2 agonist), MPLA (TLR4 agonist), imiquimod (TLR7/8 agonist) and CpG (TLR9 agonist), with triple combinations promoting antigen-specific antibody titers through a balanced overall Th1/Th2 response. Therefore, combinations of TLR adjuvants can offer broad customizability of immune responses. Combinations of TLR agonists with other PAMPs such as NOD2 and macrophage-inducible Ca²⁺-dependent lectin receptor (Mincle) ligands are also promising. Covalent linkage of CL239 (TLR7 agonist) and muramyl dipeptide (NOD2 agonist), and incorporation of the dual agonist as nanoparticles with the NP-p24 HIV vaccine, synergistically enhanced protection in mice. SummarizeTLR agonists utilize endogenous innate immune pathways to enhance vaccine adaptive immune responses. Over the past two years, the domain of adjuvants has been primarily governed by research into the COVID-19 vaccine. The driving force of this pandemic has rapidly promoted the development of the adjuvant field, and several novel adjuvants have now been incorporated into licensed vaccines for COVID-19. Beyond COVID-19, the demand for more effective adjuvants continues to grow, particularly in the areas of difficult-to-prevent infectious diseases such as cancer, malaria, tuberculosis, and HIV. Unraveling the mechanisms behind the action of TLR co-adjuvants, coupled with increased safety and efficacy research data, can help drive the development of the next generation of adjuvant platforms.

18 Oct 2023

·www.prnewswire.com

Lao PDR Reaches Incredible Milestone in Mitigating Neglected Tropical Diseases with Elimination of Lymphatic Filariasis

RTI International congratulates Lao PDR in eliminating LF — a disabling disease impacting the lives of millions of people around the world RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 /PRNewswire/ -- RTI International, a nonprofit research institute and leading international development organization, joins the Lao People's Democratic Republic (Lao PDR), World Health Organization, and the U.S. Agency for International Development (USAID) in celebrating Lao PDR's achievement of eliminating lymphatic filariasis as a public health problem. Also known as elephantiasis, lymphatic filariasis is a neglected tropical disease (NTD) that can cause swollen extremities in a person and lead to severe disfigurement and disability, as well as social and economic discrimination against those affected. As of the latest data released by WHO last week, more than 793 million people required treatment for this disease across 44 countries in Asia, Africa, the Western Pacific, and parts of the Caribbean and South America. WHO officially confirmed this week that the people of Lao PDR are no longer at risk of contracting the disease. "RTI sends our sincerest congratulations to the government of Lao PDR and its people for solving this pressing public health problem," said Tim Gabel, president and CEO of RTI International. "It is particularly significant given that Lao PDR achieved the elimination of trachoma as public health problem in 2017, demonstrating the power of national commitment to ending neglected tropical diseases." RTI supported this milestone through its leadership of USAID's Act to End NTDs | East program, which has advanced the sustainable control and elimination of NTDs in 13 countries across Africa, Asia and Latin America. RTI worked with the government of Lao PDR to compile the data and information needed to establish proof that the country had eliminated lymphatic filariasis as a public health problem. Additionally, with USAID support, RTI assisted the government to develop a plan to monitor and track progress against the disease to ensure elimination is sustained in the future. "Lao PDR is the latest example of a country that worked hard to go the last mile to reach lymphatic filariasis elimination and free its people from this disabling disease," said  Lisa Rotondo, Director of USAID's Act to End NTDs | East program at RTI. "Global momentum towards eliminating lymphatic filariasis as a public health problem, led by countries themselves, is only growing. We are proud to be among the partners that supported the Lao PDR Ministry of Health to achieve this important milestone for its people." The elimination of lymphatic filariasis in Lao PDR was supported by many partners including USAID, RTI, FHI360, WHO, Mac Foundation, and the Asian Development Bank. In addition, albendazole treatments were donated by GlaxoSmithKline through the WHO donation program for NTD medicines. The Southeast Asian country now becomes the 19th country to have achieved validation of lymphatic filariasis elimination, marking another important public health milestone for the country and globally. Recently, Bangladesh also eliminated lymphatic filariasis with support from the Act to End NTDs | East program, led by RTI. Learn more about RTI's work to control and eliminate NTDs around the globe Media Contact: Kerry Branon 919 708-8205 [email protected] SOURCE RTI International

100 Deals associated with Albendazole

External Link

KEGG	Wiki	ATC	Drug Bank
D00134	Albendazole	P02CA03	DB00518

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cystitis	Japan	GlaxoSmithKline KK	19 Jan 1994
Helminthiasis	China	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Intestinal Diseases	Phase 1	India	GSK Plc	21 Aug 2023
Helminthiasis	Preclinical	China	GSK Plc	01 Apr 2012
HIV Infections	Preclinical	United States	Smithkline Beecham	31 Aug 2001
Microsporidiosis	Preclinical	United States	Smithkline Beecham	31 Aug 2001
Protozoan Infections	Preclinical	United States	Smithkline Beecham	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06201559 (CTgov)	Phase 1	Intestinal Diseases	70	Albendazole (Albendazole IP 400 mg/400mg - Test 1 (T1))	mbwneiigdn(vlssnlnnpf) = amybbmcupn gstftplmls (waunvtnwjo, selohvcyzn - cbwmkrlbdl) View more	-	27 Jan 2025
				Albendazole (Albendazole IP 400 mg/400 mg - Test 2 (T2))	mbwneiigdn(vlssnlnnpf) = cqzbogmvin gstftplmls (waunvtnwjo, mdnuvxonqb - ohfsdpdgab) View more
NCT04326868 (Pubmed \| Antimicrob Agents Chemother)	Phase 4	Infectious Diseases	-	Albendazole 400 mg	(dhrzwydxif) = cdbbavbupv momwqmdjkp (mgirvheymm, 58 - 81) View more	-	02 Apr 2024
NCT03527732 (CTgov)	Phase 2/3	Trichuriasis	1,673	Albendazole (Albendazole in Côte d'Ivoire)	nlbippygzh(fjipzvtetz) = bnqmgdqnko afrbyijmpc (hjsodnunjq, adkdjmudpu - nodpjkiykl) View more	-	20 Mar 2024
				Albendazole+Ivermectin (Albendazole and Ivermectin in Côte d'Ivoire)	nlbippygzh(fjipzvtetz) = ncbqzfyblz afrbyijmpc (hjsodnunjq, gsyunlvsol - zjyqgcxcft) View more
NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	Phase 3	Elephantiasis, Filarial Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	tkuhkjlfop(lkupzbhilm) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) decvpqvcnh (rujibbcnpz ) View more	Positive	18 Sep 2023
				moxidectin + albendazole
PACTR202202738940158 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Hookworm Infections	225	Dual-dose albendazole	qhvjqtmjfz(roedanmgfm) = adfipfytgu xrmqagmtao (ypuhyenqyp, 90.9 - 99) View more	-	01 Jul 2023
				Single-dose albendazole	qhvjqtmjfz(roedanmgfm) = idjycwhttm xrmqagmtao (ypuhyenqyp, 75.7 - 90.2) View more
NCT04188301 (DOLF IDA/Oncho, CTgov)	Phase 2	Onchocerciasis	154	Albendazole+Ivermectin (IVM + ALB)	uobstxohnz(mxdhmfmajy) = tlpmbbofbv hhfnwtbxra (hmvkeolshv, wicibgewnv - qitegjxjkd) View more	-	10 May 2023
				albendazole+ivermectin+diethylcarbamazine (IDA x 1 Dose)	uobstxohnz(mxdhmfmajy) = qjxqayjoto hhfnwtbxra (hmvkeolshv, tuyfkwjrzm - vsodeufkro) View more
NCT04726969 (CTgov)	Phase 3	Trichuriasis \| Ascariasis \| Hookworm Infections	255	Albendazole 400 mg Oral Tablet+Moxidectin 2 mg Oral Tablet (Arm A: Moxidectin and Albendazole)	(ysxpjtsghs) = lgqzihesoe ysbormcxnw (kcqyalvipa, emhdnmphlv - mjiolospiv) View more	-	02 Feb 2023
				Albendazole 400 mg Oral Tablet (Arm B: Albendazole)	(ysxpjtsghs) = xohrneodff ysbormcxnw (kcqyalvipa, bayvvivser - jymiacilig) View more
EAN2022	Not Applicable	Encephalomyelitis	-	Levamisole	afvrsroqsi(wmqzfdixmx) = mfylhamjvj ofwlkjrayv (kvilavkacv )	-	24 Jun 2022
				Albendazole	afvrsroqsi(wmqzfdixmx) = awhskzdhox ofwlkjrayv (kvilavkacv )
NCT02899936 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Elephantiasis, Filarial	23,789	Albendazole + Diethylcarbamazine + Ivermectin	ghkiruohlp(txtunzhuvp) = The overall frequency of AEs were similar after either DA (18%) or IDA (20%) treatment yshmiiaklu (frjkpcsdap ) View more	Positive	09 Feb 2022
				Diethylcarbamazine + Albendazole
NCT02899936 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Filariasis	23,789	Ivermectin plus diethylcarbamazine and albendazole	zymbjcugcv(qpswkuauix) = About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. ysifzczyyr (hmsouofwor )	-	29 Mar 2021
				Diethylcarbamazine plus albendazole

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Albendazole

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation